MK1084-015 A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy
- Phase III
- Trial Category: Lung
Contact(s)
Mary Beth Wilwerding, RN Admin@NEcancertrials.com
Location(s)
Available at Nebraska Hematology and Oncology, Lincoln, NE location
Interested in More Information?
Please fill out the form below. Someone will get back to you as soon as possible.
"*" indicates required fields